CClinicalTrials.gg
CompletedNCT04772898Updated Mar 18, 2024Results posted

Effectiveness of a 6-week Hippotherapy Program in Children With Autism Spectrum Disorder

An interventional study of Hippotherapy in Autism Spectrum Disorder, sponsored by Creighton University. Completed at 1 site in United States. Open to participants aged 5 Years to 10 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-03-18.

Sponsored by Creighton University · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
5 Years to 10 Years
Sex
All
01

Study summary

The prevalence of autism spectrum disorders (ASD) has increased dramatically in the last decade. The increasing occurrence of ASD creates an imperative need to test the effectiveness and efficacy mechanisms of appropriate interventions. Hippotherapy (HPOT) is a treatment option that has been show beneficial for children with ASD as well as other children with developmental disorders. The current projects focuses on understanding the mechanisms of HPOT efficacy and evaluating a short-term HPOT program for children with ASD.

Read the detailed description

The incidence of autism spectrum disorders (ASD) has increased dramatically in the last decade. The latest report from the Centers for Disease Control and Prevention state that 1 in 59 children are being diagnosed with ASD and it is four times more prevalent in boys than girls. Common treatments for children with ASD are applied behavioral therapy, occupational and speech therapy, which are used solely or in combination. Hippotherapy (HPOT) is another treatment option that has been shown to positively impact various aspects of behavior. This pilot project aims to determine the effects of a 6-week HPOT program on movement and social behavior of children with ASD and to investigate the underlying mechanisms of why HPOT is successful for ASD through the coupling of physiological and temperamental responses between horse and rider. The approach involves examining these skills pre, during, and post HPOT intervention in children diagnosed with ASD. A group of aged matched children with typical development will serve as the control group. Innovative measures of physiological coupling and temperament between horse and rider as well as objective and quantitative measures of movement and social behavior and caregiver perception will be collected. The investigators anticipate that following completion of the proposed study, they will provide the necessary foundation to understand the mechanisms of HPOT, and thus provide a new framework to test clinical trials of HPOT and human-animal interaction, and ultimately improve the lives of those diagnosed with ASD and their families.

02

Conditions studied

03

In context

Autistic Disorder

1,344 studies on the registry are indexed under Autistic Disorder; 334 are open to participants now.

This study's enrollment of 30 is below the median of 45 across 1,044 interventional studies indexed under Autistic Disorder.

Browse Autistic Disorder studies →

Lead sponsor

Creighton University is the lead sponsor of 126 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 10 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

For the children with Autism Spectrum Disorders:

Inclusion criteria

Inclusion Criteria:

  1. diagnosis of ASD based upon the Autism Diagnostic Observation Schedule and parent interview,
  2. medical approval for participation in the HPOT activity,
  3. no other medical or psychiatric diagnoses besides ASD
  4. tolerate helmet on head and attachments of the movement and heart rate sensors.

The inclusion criteria for the TD children will be:

  1. no diagnosis or family history of ASD
  2. no other neurodevelopmental or musculoskeletal disorder
  3. tolerate helmet on head and attachments of the movement and heart rate sensors.
  4. medical approval for participation in the HPOT activity,

Exclusion criteria

Exclusion Criteria:

  1. under 5 years of age or over 10 years of age
  2. has a serious comorbid medical diagnosis
  3. major vision or hearing impairments
  4. severe behavioral problems
  5. an orthopedic or genetic diagnosis
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Children with Autism Spectrum Disorders

    Children with autism spectrum disorder will receive a 6 week (once per week) hippotherapy protocol. During the hippotherapy session, the researchers will monitor the heart rate variability of the horse and the rider. Both horse and rider will wear an electrode strap around the upper thorax. Heart rate recordings will be started simultaneously at the beginning of the HPOT session. To assess movement coupling between the horse and rider, five tri-axial inertial sensors (OPAL, APDM, Inc, Portland, OR) will be used. The sensors will collect actively synchronized tri-axial accelerometer and gyroscope data. One inertial sensor will be placed dorsal at the rider's pelvis, one frontal at the top of the forehead, and one frontal at the top of the sternum. The sensors on the horse will be fixed on the back of the horse on the spine level between T8 and T10 and on the head.

    Behavioral: Hippotherapy

  • Active comparator
    Children with typical development

    Children with autism spectrum disorder and with typical development will receive a 6 week (once per week) hippotherapy protocol. During the hippotherapy session, the researchers will monitor the heart rate variability of the horse and the rider. Both horse and rider will wear an electrode strap around the upper thorax. Heart rate recordings will be started simultaneously at the beginning of the HPOT session. To assess movement coupling between the horse and rider, five tri-axial inertial sensors (OPAL, APDM, Inc, Portland, OR) will be used. The sensors will collect actively synchronized tri-axial accelerometer and gyroscope data. One inertial sensor will be placed dorsal at the rider's pelvis, one frontal at the top of the forehead, and one frontal at the top of the sternum. The sensors on the horse will be fixed on the back of the horse on the spine level between T8 and T10 and on the head.

    Behavioral: Hippotherapy

Interventions

  • BehavioralHippotherapy

    The hippotherapy involves occupational therapy while being on a horse.

06

What researchers measure

Primary outcomes

  1. Social Responsiveness Scale (SRS)

    The SRS provides a clear picture of a child's social impairments, assessing social awareness, social information processing, capacity for reciprocal social communication, social anxiety/avoidance, and autistic preoccupations and traits. The SRS is a 65-item rating scale that measures autism traits over the previous 6 months in children and adolescents aged 4-18 years. Each item is scaled from 0 (never true) to 3 (almost always true), generating a total score ranging from 0 to 195.The total score of the SRS is reported below. Higher values represent worse outcome.

    Time frame: Change from Pre (baseline) to Post (after completion of 6 weeks of intervention)

  2. Postural Control

    Postural control assessment with a force platform with eyes open and eyes closed. Differences were more prevalent with eyes closed. We report a specific measure of postural control which is median frequency while standing with eyes closed. Median frequency can have a very wide range of values, but increased values of median frequency suggest faster postural control adaptations.

    Time frame: Change from Pre (baseline) to Post (6 weeks after hippotherapy intervention)

  3. Cross Sample Entropy Between the Heart Rate Sensors of the Horse and Rider

    Heart rate monitors were placed around the upper thorax of both the rider and horse and simultaneously began collecting data at the beginning of each session. Data was collected at the first, third, and sixth sessions of the intervention. We used the heart rate signals of the horse and rider to calculate the Cross approximate entropy. Cross-ApEn quantifies the regularity of patterns in a pair of related time series and is indicative of the dimensionality of control of the two signals. The calculation of Cross-ApEn is similar to approximate entropy with the exception that successive two-point vectors of one signal are compared with current and previous two-point vectors of another signal. Larger Cross-ApEn values indicate greater joint signal asynchrony while lower Cross-ApEn values indicate greater joint signal synchrony.For details on calculation of Cross-ApEn please refer to: Pincus S, Singer BH. Randomness and degrees of irregularity. Proc Natl Acad Sci USA. 1996; 93: 2083-2088.

    Time frame: During week 1, week 3 and week 6 of the treatment sessions

Secondary outcomes

  1. Correlation Between Horse Temperament and Therapeutic Outcomes

    Correlation estimate between horse temperament and treatment effectiveness

    Time frame: from baseline to 6 weeks

  2. Aberrant Behavior Checklist

    This is a questionnaire completed by the caregivers that assesses irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, inappropriate speech

    Time frame: Change from baseline to 6 weeks

07

Results

Posted Mar 18, 2024

Participant flow

Participant flow — Overall Study
MilestoneChildren With Autism Spectrum DisorderChildren With Typical Development
Started1515
Completed1514
Not completed01
Withdrew: Withdrawal by subject01

Outcome measures

PrimarySocial Responsiveness Scale (SRS)

The SRS provides a clear picture of a child's social impairments, assessing social awareness, social information processing, capacity for reciprocal social communication, social anxiety/avoidance, and autistic preoccupations and traits. The SRS is a 65-item rating scale that measures autism traits over the previous 6 months in children and adolescents aged 4-18 years. Each item is scaled from 0 (never true) to 3 (almost always true), generating a total score ranging from 0 to 195.The total score of the SRS is reported below. Higher values represent worse outcome.

Time frame:
Change from Pre (baseline) to Post (after completion of 6 weeks of intervention)
Reported as:
Mean · Points
Social Responsiveness Scale (SRS)
PointsChildren With Typical DevelopmentChildren With Autism Spectrum Disorder
Pre16.5 ± 12.489.06 ± 27.3
Post14.5 ± 12.379.8 ± 29.5
PrimaryPostural Control

Postural control assessment with a force platform with eyes open and eyes closed. Differences were more prevalent with eyes closed. We report a specific measure of postural control which is median frequency while standing with eyes closed. Median frequency can have a very wide range of values, but increased values of median frequency suggest faster postural control adaptations.

Time frame:
Change from Pre (baseline) to Post (6 weeks after hippotherapy intervention)
Reported as:
Mean · Hz
Postural Control
HzChildren With Typical DevelopmentChildren With Autism Spectrum Disorder
Pre0.525 ± 0.170.48 ± 0.18
Post0.53 ± 0.210.57 ± 0.15
PrimaryCross Sample Entropy Between the Heart Rate Sensors of the Horse and Rider

Heart rate monitors were placed around the upper thorax of both the rider and horse and simultaneously began collecting data at the beginning of each session. Data was collected at the first, third, and sixth sessions of the intervention. We used the heart rate signals of the horse and rider to calculate the Cross approximate entropy. Cross-ApEn quantifies the regularity of patterns in a pair of related time series and is indicative of the dimensionality of control of the two signals. The calculation of Cross-ApEn is similar to approximate entropy with the exception that successive two-point vectors of one signal are compared with current and previous two-point vectors of another signal. Larger Cross-ApEn values indicate greater joint signal asynchrony while lower Cross-ApEn values indicate greater joint signal synchrony.For details on calculation of Cross-ApEn please refer to: Pincus S, Singer BH. Randomness and degrees of irregularity. Proc Natl Acad Sci USA. 1996; 93: 2083-2088.

Time frame:
During week 1, week 3 and week 6 of the treatment sessions
Reported as:
Mean · Unitless
Cross Sample Entropy Between the Heart Rate Sensors of the Horse and Rider
UnitlessChildren With Autism Spectrum DisorderChildren With Typical Development
1st session0.685 ± 0.090.512 ± 0.25
3rd session0.644 ± 0.180.578 ± 0.16
6th session0.681 ± 0.180.564 ± 0.18
SecondaryCorrelation Between Horse Temperament and Therapeutic Outcomes

Correlation estimate between horse temperament and treatment effectiveness

Time frame:
from baseline to 6 weeks

Results for this outcome have not been posted.

SecondaryAberrant Behavior Checklist

This is a questionnaire completed by the caregivers that assesses irritability, social withdrawal, stereotypic behavior, hyperactive/noncompliance, inappropriate speech

Time frame:
Change from baseline to 6 weeks

Results for this outcome have not been posted.

Adverse events

Collected over During the intervention and participation to the study which was 8 weeks.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Children With Typical Development0/15 (0%)0/15 (0%)0/15 (0%)
Children With Autism Spectrum0/15 (0%)0/15 (0%)0/15 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Children With Autism Spectrum DisordersChildren With Typical DevelopmentTotal
<=18 years151530
Between 18 and 65 years000
>=65 years000
Age, Continuous
Age, Continuous(years)Children With Autism Spectrum DisordersChildren With Typical DevelopmentTotal
Mean8 ± 1.977.8 ± 1.447.9 ± 1.715
Sex: Female, Male
Sex: Female, Male(Participants)Children With Autism Spectrum DisordersChildren With Typical DevelopmentTotal
Female4913
Male11617
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Children With Autism Spectrum DisordersChildren With Typical DevelopmentTotal
Hispanic or Latino112
Not Hispanic or Latino141428
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Children With Autism Spectrum DisordersChildren With Typical DevelopmentTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American000
White131528
More than one race101
Unknown or Not Reported000
Social Responsiveness Scale (SRS)
Social Responsiveness Scale (SRS)(Points)Children With Autism Spectrum DisordersChildren With Typical DevelopmentTotal
Mean16.5 ± 12.489.06 ± 27.352.78 ± 19.85
08

Study locations

1 site
  • Hearthland Equine Therapeutic Riding Academy
    Gretna, Nebraska 68028, United States
09

References and documents

Study documents

  • Protocol and statistical analysis plan · Jan 18, 2021
  • Informed consent form · Jan 18, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04772898
Lead sponsor
Creighton University
Responsible party
Anastasia Kyvelidou (Assistant Professor, Creighton University) — Principal investigator
First posted
Feb 26, 2021
Start date
Sep 7, 2021
Primary completion
Jul 31, 2022
Completion
Jul 31, 2022
Results posted
Mar 18, 2024
Last update
Mar 18, 2024

Study contacts

Anastasia Kyvelidou, PhD
principal investigator · Creighton University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion